SMP 500
structure in first source
Also Known As:
N-(2,6-bis(1-methylethyl)phenyl)-N'-(1-butyl-1,2-dihydro-2-oxo-4-(3-(3-pyridylmethoxy)phenyl)-1,8-naphthyridin-3-yl)urea nitrate; SMP-500
Networked: 2
relevant articles (0 outcomes,
0 trials/studies)
for this Bio-Agent,
Comments
Bio-Agent Context: Research Results
Experts
| 1. | Sato, Yumi F: 1 article (10/2002) |
| 2. | Ohashi, Naohito: 1 article (10/2002) |
| 3. | Kino, Kouichi: 1 article (10/2002) |
| 4. | Ioriya, Katsuhisa: 1 article (10/2002) |
| 5. | Shimizu, H: 1 article (05/2002) |
| 6. | Ohashi, N: 1 article (05/2002) |
| 7. | Noguchi, T: 1 article (05/2002) |
| 8. | Muraoka, M: 1 article (05/2002) |
| 9. | Ioriya, K: 1 article (05/2002) |
| 10. | Fujita, K: 1 article (05/2002) |
Related Diseases
| 1. | Hypercholesterolemia
10/01/2002
- "This finding supports the therapeutic potential of SMP-500 for the treatment of human hypercholesterolemia."
05/01/2002 - "These results indicate that SMP-500 is a potent and competitive ACAT inhibitor and may have a therapeutic potential for treating hypercholesterolemia and atherosclerosis." Order ALL the reference details at left... |
| 2. | Atherosclerosis (Atheroma)
05/01/2002
- "These results indicate that SMP-500 is a potent and competitive ACAT inhibitor and may have a therapeutic potential for treating hypercholesterolemia and atherosclerosis."
Order ALL the reference details at left... |
| 3. | Hyperlipidemias (Hyperlipidemia)
10/01/2002
- "Effect of SMP-500, a novel acyl-CoA:cholesterol acyltransferase inhibitor, on serum cholesterol level and LDL cholesterol clearance in hamsters with induced hyperlipidemia."
Order ALL the reference details at left... |
Related Drugs and Biologics
| 1. | LDL Cholesterol
|
| 2. | Sterol O-Acyltransferase
|
| 3. | Cholesterol
|
TREATMENT OPTIONS
for Hypercholesterolemia,
Ranking and Evidence
for Hypercholesterolemia,
Ranking and Evidence
CureHunter Patient-Physician Summary Reports collect in one document all the
medications ever reported in the US National Library of Medicine—1949 to the present—to
be effective against your target disease.
Analytic charts allow you and your physicians to see at a glance the
treatment options—including new, promising, off-label and experimental.
- Free Updates for 1 Year
- All 412 Outcomes
- Top 200 Key Drugs and Biologics
- Top 50 Key Therapies and Procedures
- Detailed History Charts
- Full Research Evidence References
- Sample PDF Report on Psoriasis >>
| Price: | $8.50 USD
& Delivery via
PDF download
updates for 1 year |
Research Interface PRO
- Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
- Enable Experts: Quickly identify key researchers and their publications
- Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
- Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
- Research Network: Explore drug and disease relationships visually
- Enable Mobile Interface: Access from your cellphone, iPhone or PDA
| Price: | $45.00 USD
access via web interface 1 year subscription |